X
X4 Pharmaceuticals Inc (XFOR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$3.09
+0.26 (+9.19%)
Market Cap: $288.98M
Last updated: Nov 17, 2026 at 4:33 PM ET
X4 Pharmaceuticals Inc (XFOR) Valuation Multiples
X4 Pharmaceuticals (XFOR) trades at 23.6x sales and 2.8x book value. Its P/B of 2.8x is above its 5-year median of 2.7x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 23.6x |
| Price to book | 2.8x |
| PEG | N/A |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 2.8x | 2.7x | N/A |
Valuation History
Over the 6 of the 9 year ends shown that have a P/S, its P/S ranged from 0.9x in 2025 to 190.3x in 2022. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $4.00 | 0.9x | 2.4x |
| 2024 | $22.03 | 58.0x | 6.7x |
| 2023 | $25.18 | 54.5x | 3.3x |
| 2022 | $29.82 | 190.3x | 1.4x |
| 2021 | $68.77 | N/A | 1.0x |
| 2020 | $193.09 | 50.2x | 1.8x |
| 2019 | $321.32 | 5.3x | 1.4x |
| 2018 | $417.93 | N/A | 33.2x |
| 2017 | $2,298.64 | N/A | N/A |
Frequently Asked Questions About XFOR
What is XFOR's price to sales ratio?
X4 Pharmaceuticals has a price to sales ratio of 23.6x.
XFOR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors